Researchers at QT Sense are developing a platform called ONCO-Q that uses nanodiamonds to measure the metabolic activity of individual colon cancer cells. This technology aims to move beyond standardized treatments by revealing how tumors respond to therapies before they are administered, potentially optimizing dosage and improving patient outcomes. The University of Groningen and Life Cooperative are collaborating with QT Sense on this project, including building a demonstration device to track the platform’s progress toward clinical deployment within two years.
Nanodiamond Sensors Measure Individual Cancer Cell Metabolism
Nanodiamonds within the ONCO-Q platform enable measurement of metabolic activity at the level of individual cancer cells, a level of detail exceeding current diagnostic capabilities. This detailed analysis provides insight into how tumor cells respond to potential therapies before treatment begins, moving beyond standardized approaches to cancer care. QT Sense reports this capability is focused initially on colon cancer, but the underlying technology is adaptable to other malignancies.
This collaborative effort signals a deliberate push to translate laboratory research into a deployable instrument within two years, according to the company, and consumables and assay kits are also being developed to ensure the platform is both powerful and scalable for widespread use. A demonstration device is currently under construction at QT Sense’s lab, providing a means to showcase the ONCO-Q platform and monitor its development in real time, the company says. The company believes this precision will not only improve patient outcomes but also lower healthcare costs and optimize resource allocation.
See today’s quantum computing news on Quantum Zeitgeist for the latest breakthroughs in qubits, hardware, algorithms, and industry deals.
